BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35601131)

  • 1. Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.
    Chan HLY; Vogel A; Berg T; De Toni EN; Kudo M; Trojan J; Eiblmaier A; Klein HG; Hegel JK; Sharma A; Madin K; Rolny V; Lisy MR; Piratvisuth T
    JGH Open; 2022 May; 6(5):292-300. PubMed ID: 35601131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
    Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.
    Kaneko S; Kurosaki M; Tsuchiya K; Yasui Y; Hayakawa Y; Inada K; Tanaka Y; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Takahashi Y; Nakanishi H; Izumi N
    PLoS One; 2022; 17(3):e0265235. PubMed ID: 35271670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population.
    Sharma B; Srinivasan R; Chawla YK; Kapil S; Saini N; Singla B; Chakraborthy A; Kalra N; Duseja A; Dhiman RK
    Hepatol Int; 2010 Jul; 4(3):569-76. PubMed ID: 21063479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
    Xing H; Zheng YJ; Han J; Zhang H; Li ZL; Lau WY; Shen F; Yang T
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):487-495. PubMed ID: 30257796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Kobeissy A; Merza N; Al-Hillan A; Boujemaa S; Ahmed Z; Nawras M; Albaaj M; Dahiya DS; Alastal Y; Hassan M
    J Clin Med Res; 2023 Jul; 15(7):343-359. PubMed ID: 37575350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population.
    Yu R; Ding S; Tan W; Tan S; Tan Z; Xiang S; Zhou Y; Mao Q; Deng G
    Hepat Mon; 2015 Jul; 15(7):e28806. PubMed ID: 26300931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
    Chen J; Tang D; Xu C; Niu Z; Li H; Li Y; Zhang P
    Lab Med; 2021 Jul; 52(4):381-389. PubMed ID: 33159511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation.
    Si YQ; Wang XQ; Fan G; Wang CY; Zheng YW; Song X; Pan CC; Chu FL; Liu ZF; Lu BR; Lu ZM
    Infect Agent Cancer; 2020 Nov; 15(1):70. PubMed ID: 33292429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
    Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.
    Wang X; Zhang W; Liu Y; Gong W; Sun P; Kong X; Yang M; Wang Z
    Infect Agent Cancer; 2017; 12():47. PubMed ID: 28852419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.